Navigation Links
angelMD Completes Investment in Bleeding Detection Medical Device Company
Date:6/15/2017

angelMD announced the closure of a new syndicate investment in Saranas, a promising new medical device startup. Dan Parsley, angelMD’s SVP of Corporate Development, served as the syndicate leader for this first investment in Saranas by angelMD members, and this angelMD syndicate is part of Saranas’ recently announced $4 million Series B financing round.

Saranas is working to create a way to quickly and accurately diagnose complications in vascular access procedures, while lowering patient and provider costs. Every year, twenty million American patients undergo these procedures to provide longer term access for intravenous (IV) medical treatments, and as many as a million of these patients experience life-threatening complications as a result of an inability to quickly account for problems like internal bleeding. These issues cost patients and providers a collective $8.4B dollars each year.

“With the growth of value-based insurance reimbursements combined with the increasing popularity of intravenous heart procedures, patients and doctors are demanding better procedural outcomes,” said Parsley. “This innovative real-time bleeding detection device by Dr. Razavi is designed to be integrated directly into common catheter sheaths, and I’m confident many existing cardiac medical device companies will see the immediate value of this technology.”

Saranas is angelMD’s first investment of technology originating from the prestigious Texas Heart Institute at the Texas Medical Center.

Saranas CEO Zaffer Syed said, “We are thrilled to be adding angelMD to our investor base. With access to physician investors, angelMD brings a strong track record of adding real value to its portfolio companies. This Series B financing reflects a deep commitment to Saranas’ innovative approach for enhancing patient outcomes during vascular access procedures.”

“Saranas has the management team and an experienced board that will be able to see this innovative technology through FDA clearance, and we are excited to help this company grow and become an industry leader,” concluded Parsley.

About angelMD
angelMD is an investment platform and marketplace connecting innovative medical startups, physicians, investors and industry partners. Leading physicians from all over the US have joined the angelMD Scientific Advisory Board and Leaders Club to help source, evaluate and advise companies in biotechnology, medical device and healthcare technology. For more information, visit http://www.angelmd.co.

About Saranas
Saranas is a privately held Houston, Texas-based medical device company focused on improving patient outcomes through early detection of internal bleeding complications. The company’s patented introducer sheath technology for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more on their pioneering technology, visit

Read the full story at http://www.prweb.com/releases/2017/06/prweb14428796.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. 3 angelMD Startups Make Livestrong Big C Semi-finals
2. BGI-Shenzhen Completes Acquisition of Complete Genomics
3. Novira Therapeutics Completes $25 Million Series A Financing
4. bioRASI Completes Acquisition of Ukrainian CRO
5. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
6. St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
7. Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs
8. Oligomerix, Inc. Completes Series B Financing
9. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
10. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
11. Boston Scientific Completes $1.05 Billion Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2019)... ... July 02, 2019 , ... Leading Regenerative Veterinary Medicine ... Pharm: Where Beasts Meet Biotech. The film focuses on regenerative veterinary medicine as ... Animal Pharm was recently included in the Brentwood and Pacific Palisades International ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... network with the appointment of Biofeedback Tech Ltd as its authorised ... an essential part of many therapeutic treatments and clinical assessment protocols to treat ...
(Date:6/11/2019)... N.C. (PRWEB) , ... June 11, 2019 , ... ... extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to incorporate ... cloning ability. In a test on mice, MSC-EVs also increased the cells’ ability ...
(Date:5/31/2019)... ... 30, 2019 , ... Object Pharma, Inc., a startup company ... Metabiologics, Inc., a globally recognized leader in the production and sale of botulinum ... a full spectrum of botulinum neurotoxins, as well as a CDC approved facility ...
Breaking Biology Technology:
(Date:6/16/2019)... , ... June 14, 2019 , ... ... invited to lecture at the fifth annual Neodent World Congress. Attended by thousands ... innovative progress and latest advancements in the world of dentistry. The three-day event ...
(Date:6/14/2019)... , ... June 14, 2019 , ... Molecular diagnostics segment ... to be $8,760 million in 2019. Major segments that are expected to drive ... all broken out and forecasted as segments in Kalorama’s The World Molecular Diagnostics ...
(Date:6/13/2019)... HORSHAM, Pa. (PRWEB) , ... June 13, 2019 ... ... Ancillare, LP , the first organization exclusively serving the end-to-end clinical and ancillary ... companies, as well as contract and medical research organizations, today announced it will ...
Breaking Biology News(10 mins):